Wegovy vs Mounjaro for PCOS Weight Loss

If you're managing PCOS-related weight challenges, two injectable medications - Wegovy and Mounjaro - are generating attention. Both target insulin resistance, a core issue in PCOS, and have shown impressive weight loss results. Wegovy (semaglutide), a GLP-1 receptor agonist, is FDA-approved for chronic weight management. Mounjaro (tirzepatide), a dual GLP-1/GIP receptor agonist, is FDA-approved for type 2 diabetes but frequently prescribed off-label for weight loss. Here's a quick breakdown:

• Wegovy: Offers up to 20.7% weight loss with the new 7.2 mg dose and improves insulin sensitivity, menstrual cycles, and acne.
• Mounjaro: Delivers up to 22.1% weight loss with its dual-action mechanism, tackling insulin resistance and inflammatory fat.

Quick Comparison

Feature	Wegovy (Semaglutide)	Mounjaro (Tirzepatide)
Max Weight Loss	20.7% (7.2 mg dose)	22.1% (15 mg dose)
FDA Approval	Chronic weight management	Type 2 diabetes
PCOS Benefits	Reduces insulin resistance, improves cycles	Targets insulin resistance, reduces inflammation
Side Effects	More nausea at higher doses	Less nausea due to GIP action
Cost (Monthly)	~$1,350	~$1,080

Both medications offer meaningful benefits, but your choice depends on your health profile, goals, and tolerability. Keep in mind that lifestyle changes are essential for maintaining weight loss. Consult your healthcare provider to determine the best option for you.

Weight loss drugs fill a gap for women with hormonal disorder PCOS | REUTERS

What is Wegovy?

Wegovy is a prescription medication containing semaglutide, a GLP-1 receptor agonist. It’s approved for managing chronic weight issues in adults and adolescents aged 12 and older who meet specific BMI requirements. While Wegovy isn’t specifically approved for treating PCOS, it’s often prescribed off-label to address the obesity and insulin resistance commonly associated with the condition.

The medication is administered either as a once-weekly injection or a once-daily oral tablet. Treatment begins with a low dose, which is gradually increased over four to five months to minimize gastrointestinal side effects.

How Wegovy Works for PCOS

Wegovy supports weight management through three key actions:

• It signals the brain to create a feeling of fullness and reduces food cravings (sometimes called "food noise").
• It slows the rate at which the stomach empties.
• It prompts the pancreas to release insulin in response to carbohydrate intake while also instructing the liver to produce less glucose.

"GLP-1 is going to travel to the brain, and signal the brain that you're getting full, it's time to stop eating, and it's also going to... slow gastric emptying."

• Thomas Wadden, PhD, Professor of Psychology in Psychiatry

For women with PCOS, Wegovy has shown benefits in both weight loss and metabolic health. Research highlights a reduction in HOMA-IR and fasting insulin levels, with 80% of patients experiencing normalization of blood sugar levels within three months. Additionally, between 71% and 80% of patients with PCOS who responded to the treatment reported regular menstrual cycles. Improvements in acne (33%) and reduced hirsutism (29%) were also noted.

Weight Loss Results with Wegovy

Clinical trials have demonstrated that Wegovy can lead to significant weight loss. In the STEP 1 trial, participants taking the standard 2.4 mg weekly dose lost an average of 14.9%–15% of their body weight over 16 months, compared to just 2.4% in the placebo group. A newer 7.2 mg dose, approved in January 2026, showed even greater results, with participants losing an average of 20.7% of their body weight at 72 weeks. Nearly one-third of those participants achieved a weight loss of 25% or more.

For women with PCOS, the outcomes are equally encouraging. A real-world study of 58 obese women with PCOS reported an average weight loss of 12.6 kg (11.4% of total body weight), with 81% of participants losing more than 5% of their body weight. In another study, PCOS patients unresponsive to lifestyle changes lost an average of 7.6 kg (with a BMI reduction of 3.1) over three months on a 0.5 mg weekly dose. Impressively, 80% of these patients achieved more than a 5% reduction in body weight.

"Semaglutide, independently of its effect on body weight, may represent a good alternative to metformin for improving insulin resistance and preventing type 2 diabetes in PCOS."

• Enrico Carmina, Endocrinology Unit, University of Palermo

Next, we’ll explore Mounjaro’s profile and its role in addressing PCOS-related obesity.

What is Mounjaro?

Mounjaro is a prescription injectable medication containing tirzepatide, a first-of-its-kind dual agonist that targets both GLP-1 and GIP receptors. While it’s FDA-approved for managing type 2 diabetes in adults and children aged 10 and older, it’s also widely used off-label for weight management. Interestingly, the same active ingredient is marketed under the name Zepbound specifically for treating obesity.

For women with PCOS, Mounjaro addresses a critical underlying issue - insulin resistance. This condition drives high insulin levels, which in turn cause the ovaries to produce excess androgens. The medication is administered once a week using a pre-filled pen that can be injected into the stomach, thigh, or upper arm.

What makes Mounjaro particularly effective is its dual action. The GLP-1 component helps regulate appetite and blood sugar, while the GIP component works on inflammatory white adipose tissue, which is often problematic in PCOS.

"The GIP targets white adipose tissue, which is an inflammatory type of fat... This can improve the function of white adipose tissue, which ultimately helps with triglyceride levels and blood sugar."

• Dr. Holly Lofton, M.D., Director of the Medical Weight Management Program, NYU Langone Health

Let’s dive deeper into how Mounjaro tackles PCOS-specific challenges.

How Mounjaro Works for PCOS

Mounjaro’s unique dual-receptor mechanism tackles PCOS-related weight gain and metabolic issues through several pathways. The GLP-1 component signals the brain to curb appetite and reduce food cravings, slows down stomach emptying, and stimulates insulin release after carbohydrate consumption. Meanwhile, the GIP component enhances appetite suppression and directly targets inflammatory white adipose tissue.

By improving insulin signaling, Mounjaro lowers the elevated insulin levels that contribute to excessive androgen production. This helps restore hormonal balance and may even support regular ovulation. Research has shown that tirzepatide can boost adiponectin levels - a hormone crucial for glucose and lipid metabolism - by as much as 26%.

"Dual agonism from GIP provides more of a delay in gastric emptying and has a slight antiemetic effect... so it causes less nausea even though the stomach is emptying more slowly."

• Dr. Holly Lofton, M.D.

These mechanisms not only address hormonal and metabolic imbalances but also lead to significant weight loss.

Weight Loss Results with Mounjaro

The results from clinical trials and real-world use are impressive. In the SURMOUNT-5 trial, participants taking the maximum 15 mg dose of Mounjaro experienced an average weight loss of 20.2% over 72 weeks. Real-world data from 2025 showed even better outcomes - patients using tirzepatide alongside behavioral support lost an average of 22.1% of their starting weight within 12 months, with 95.2% achieving at least a 10% reduction in body weight. For individuals with type 2 diabetes, a condition often linked to PCOS, the highest dose led to an average weight loss of 15.7%.

Beyond weight loss, Mounjaro offers substantial metabolic improvements. A meta-analysis of GLP-1 receptor agonists in women with PCOS highlighted reductions in BMI, body weight, waist circumference, and insulin resistance (HOMA-IR). Additionally, a three-year study demonstrated that tirzepatide reduced the risk of progressing from prediabetes to type 2 diabetes by 94%. Long-term data revealed a sustained average weight reduction of 19.7% at 176 weeks.

Next, we’ll explore how Mounjaro compares to Wegovy for addressing PCOS-related weight loss.

Wegovy vs Mounjaro for PCOS Weight Loss

Managing PCOS-related weight gain requires a deep understanding of how insulin resistance and hormonal imbalances interact. Both Wegovy and Mounjaro target similar pathways, but their differences in mechanisms, effectiveness, and dosing can lead to varied outcomes. Here's a closer look at how these medications compare in the context of weight loss for women with PCOS.

Weight Loss Effectiveness

When comparing weight loss results, Mounjaro generally outperforms Wegovy at their standard maximum doses. According to the SURMOUNT-5 trial, patients on Mounjaro 15 mg experienced an average weight loss of 20.2%, while those on Wegovy 2.4 mg achieved 13.7% over 72 weeks. Real-world data from 2025 showed similar trends, with Mounjaro users losing an average of 22.1% of their starting weight compared to 17.1% for Wegovy users, when paired with behavioral support.

However, the introduction of Wegovy 7.2 mg in January 2026 changed the landscape. The STEP UP trial revealed that this higher dose allowed patients to achieve an average weight loss of 20.7%, putting it on par with Mounjaro's maximum dose.

"The STEP UP trial demonstrated that we can increase the dose of semaglutide and achieve greater weight loss than previously seen... This may offer another option to people who do not attain their weight goals."

• Sean Wharton, Lead Study Author, Wharton Medical Clinic

When looking at the percentage of patients achieving clinically meaningful weight loss, Mounjaro still leads. In 2025, 95.2% of Mounjaro users achieved at least 10% weight loss, compared to 83.1% of Wegovy 2.4 mg users. For women with PCOS, where even a 5–10% weight reduction can improve menstrual cycles and fertility, both medications offer significant benefits.

Feature	Wegovy (Semaglutide)	Mounjaro (Tirzepatide)
Drug Class	GLP-1 receptor agonist	Dual GLP-1/GIP receptor agonist
Max Weight Loss (Clinical)	20.7% (at 7.2 mg dose)	20.2%–22.5% (at 15 mg dose)
Patients Achieving ≥10% Weight Loss	83.1% (at 2.4 mg)	95.2% (at 15 mg)
PCOS Benefit	Reduces BMI, waist circumference, and HOMA-IR	Superior blood sugar/insulin control
Cardiovascular Approval	FDA-approved to reduce MACE risk by 20%	Not currently approved for MACE

Effects on Insulin Resistance and Hormones

Both medications address insulin resistance, a key driver of PCOS-related weight gain, but they do so differently. Wegovy works exclusively through GLP-1 receptors, improving insulin sensitivity and reducing insulin levels, which can lower androgen production. Mounjaro, on the other hand, uses a dual receptor mechanism, targeting both GLP-1 and GIP pathways. This dual action enhances blood sugar control and reduces inflammation in adipose tissue.

A 2024 meta-analysis focusing on PCOS patients found that GLP-1 receptor agonists significantly reduce BMI, waist circumference, and HOMA-IR (a measure of insulin resistance). Additionally, these medications can lower total testosterone levels by about 33% in women with PCOS. Both drugs also improve fasting insulin and glucose levels during oral glucose tolerance tests.

For women with severe insulin resistance, Mounjaro's dual-hormone approach may offer enhanced metabolic benefits. However, Wegovy has a distinct advantage for patients with cardiovascular risks, as it is FDA-approved to reduce major adverse cardiovascular events (MACE) by 20%, a benefit Mounjaro does not currently provide.

Dosing and Administration

Both Wegovy and Mounjaro are once-weekly injections, administered in the stomach, thigh, or upper arm. Their dosing schedules and options, however, differ significantly.

• Wegovy: Starts at 0.25 mg weekly, gradually increasing every four weeks to a maintenance dose of either 2.4 mg or 7.2 mg. The higher 7.2 mg dose is only available to patients who tolerate the 2.4 mg dose well and is delivered using three 2.4 mg pens. Wegovy also offers a once-daily oral tablet option, which must be taken first thing in the morning with no more than 4 oz of water, at least 30 minutes before eating or taking other medications.
• Mounjaro: Starts at 2.5 mg weekly, increasing every four weeks to one of three maintenance doses - 5 mg, 10 mg, or 15 mg. This flexibility allows for more personalized dosing based on individual needs and tolerability.

For women with PCOS, there’s an important consideration: Mounjaro may interfere with oral contraceptive absorption. Patients are advised to use non-oral contraceptive methods for four weeks after starting treatment and following each dose increase. Additionally, both medications should be discontinued at least two months before a planned pregnancy.

Storage instructions also vary slightly. Wegovy pens can be kept at room temperature for up to 28 days after first use, while Mounjaro pens are limited to 21 days. Both should be refrigerated until their first use. These differences in dosing and storage can influence patient preferences and experiences.

sbb-itb-6dba428

Side Effects and Safety

Common Side Effects

Wegovy and Mounjaro share many gastrointestinal side effects. In the first month of treatment, nausea is reported by 31.5% of Wegovy users and 27.8% of Mounjaro users, while constipation affects 31.5% and 29.2% of users, respectively. Fatigue is another common complaint, impacting 24.6% of Wegovy users and 21.5% of Mounjaro users during this initial period.

The good news? These side effects usually lessen over time as your body adjusts. By the 12th month, nausea drops significantly - down to 3.1% for Wegovy and 10.5% for Mounjaro. Additionally, 67.7% of Wegovy users and 60.3% of Mounjaro users report experiencing no side effects after a year of treatment.

Side Effect (Month 1)	Wegovy (Semaglutide)	Mounjaro (Tirzepatide)
Nausea	31.5%	27.8%
Constipation	31.5%	29.2%
Fatigue	24.6%	21.5%
No Side Effects (Month 12)	67.7%	60.3%

Interestingly, Mounjaro may cause less nausea compared to Wegovy. This is due to its GIP component, which has an antiemetic effect that helps counterbalance the nausea caused by its GLP-1 action.

"Dual agonism from GIP provides more of a delay in gastric emptying and has a slight antiemetic effect... so it causes less nausea even though the stomach is emptying more slowly." - Dr. Holly Lofton, Professor of Medicine and Surgery, NYU Grossman School of Medicine

To manage these side effects effectively, it’s crucial to follow your prescribed dose escalation schedule, stay well-hydrated, and rotate injection sites weekly. Hair loss, another potential side effect, is linked to rapid weight loss and is reported by 5.4% of Wegovy users and 9.6% of Mounjaro users after 12 months. While these issues can be concerning, they’re manageable with careful monitoring and support from your healthcare provider.

Long-Term Safety

Beyond the typical side effects, there are important long-term safety considerations for both Wegovy and Mounjaro. Both medications carry an FDA black-box warning about the risk of thyroid C-cell tumors. They are not recommended for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Serious side effects are rare, occurring in fewer than 2% of patients. These can include acute pancreatitis, gallbladder disease (such as gallstones), and acute kidney injury. For example, gallbladder disease was reported in 0.6% of tirzepatide (Mounjaro) users, compared to 0% in placebo groups.

Higher doses of Wegovy, such as the 7.2 mg option, are linked to an increased likelihood of gastrointestinal issues - 70.8% compared to 61.2% for the 2.4 mg dose. Some users also experience tingling or numbness (dysaesthesia), which affects 22.9% of patients at higher doses, though these symptoms typically resolve with continued use.

Neither medication is suitable during pregnancy, as weight loss during pregnancy can harm the fetus. Treatment should be discontinued at least two months before attempting to conceive. Additionally, women with diabetic retinopathy should schedule regular eye exams, as rapid improvements in glucose control may temporarily worsen this condition.

If you’re using metformin or other insulin-sensitizing medications for PCOS, combining them with Wegovy or Mounjaro can increase the risk of hypoglycemia. Regular blood sugar monitoring and potential dose adjustments are key to staying safe in these cases.

Cost and Access in the United States

Price Comparison

For many women managing PCOS, the steep price of medications can be a significant hurdle. If you're paying out of pocket, Wegovy costs around $1,350 per month, while Mounjaro runs about $1,080 per month. Unfortunately, most insurance plans don’t cover weight-loss medications unless they're tied to a diabetes diagnosis.

"GLP-1s... are a viable treatment option for managing PCOS metabolic symptoms, but most insurance companies are not willing to cover them without approval from the FDA." - Dr. Hayley Miller, Medical Director at Nurx Weight Management

Here’s a quick breakdown of the costs:

Medication	List Price (Monthly)	Self-Pay / Discounted Price
Wegovy (Injection)	~$1,350	$199 (intro) / $349 (maintenance)
Mounjaro	~$1,080	$1,075–$1,159 (GoodRx estimate)

Both medications come with savings programs. For patients with eligible commercial insurance, costs can drop to as little as $25 per month. Wegovy also offers a direct pharmacy option, starting at $199 for the first two months, then increasing to $349 per month. However, as Dr. Ethan Lazarus points out, cost remains a major obstacle for many.

To navigate these financial challenges, some patients are turning to telehealth services for more affordable options.

Getting Treatment Through Telehealth

With high costs and insurance restrictions, telehealth has become a lifeline for those seeking treatment. Services like Oana Health connect patients with licensed professionals who specialize in PCOS. Through virtual consultations, these platforms offer personalized, prescription-based treatments delivered straight to your door - with free shipping included.

What makes telehealth especially valuable is the ongoing support it provides. For women with PCOS, who often face delays in diagnosis and require tailored care for their unique metabolic needs, this personalized approach can make all the difference.

Patient Outcomes and Experience

Patient Success with Treatment

When it comes to managing PCOS, patient experiences provide a deeper understanding of both the successes and challenges beyond just clinical results. Real-world data highlights notable differences between treatments: users of Mounjaro reported an average weight loss of 22.1% of their starting weight over 12 months, compared to 17.1% for those on Wegovy. A 2025 study published in JMIR Formative Research, led by Robbie Puddick (RNutr), tracked 209 Mounjaro users and 130 Wegovy users enrolled in the Second Nature remote weight management program. The findings were striking - 83.7% of Mounjaro users lost at least 15% of their starting weight, while 56.2% of Wegovy users achieved this milestone.

But weight loss is just one part of the story. Many women with PCOS report improvements in their overall quality of life. In one real-world study focused on obese women with PCOS, 50% experienced better menstrual regularity, 33% saw improvements in acne, and 29% noticed a reduction in unwanted hair growth. Beyond physical changes, many patients describe a healthier relationship with food. As one user shared:

"Cravings and food noise are gone. I finally feel confident in the healthy habits I've built. I am no longer prediabetic." – Daisy R., Noom User

Despite these successes, the journey isn’t without its hurdles.

Common Treatment Challenges

For many patients, the early stages of treatment come with gastrointestinal side effects. Roughly 30% of users experience symptoms like nausea, though these tend to diminish over time. For example, nausea among Wegovy users drops to just 3.1% by the 12-month mark. That said, side effects can still lead to treatment discontinuation for some - between 3.3% and 6.2% of patients stop using the medication due to adverse reactions.

Another challenge is maintaining weight loss over the long term. Without lasting lifestyle changes, studies show that two-thirds of the weight lost is typically regained within a year. This highlights the importance of pairing medication with behavioral support, such as consultations with dietitians and habit-tracking tools. Programs like Oana Health offer tailored support for women managing PCOS, providing continuous access to licensed professionals who understand the unique metabolic challenges associated with the condition.

Additionally, some patients report temporary hair loss during treatment - affecting 5.4% of Wegovy users and 9.6% of Mounjaro users after 12 months. This side effect is usually linked to rapid weight loss rather than the medication itself. While these challenges can be frustrating, they underscore the need for a comprehensive approach to weight management and PCOS care.

Conclusion

Wegovy and Mounjaro both offer promising options for managing PCOS-related weight loss, though they operate through distinct mechanisms. Mounjaro’s dual GLP-1/GIP pathway often results in greater weight loss - around 22% on average compared to Wegovy’s 15% at standard doses - and has a more direct impact on insulin resistance. However, the newer high-dose Wegovy (7.2 mg) has shown comparable results, with an average weight loss of 20.7%, aligning closely with the 20.2% achieved using Mounjaro’s maximum dose.

But numbers alone don’t tell the whole story. As Dr. Sarah Chen, MD, a Board-Certified Endocrinologist, explains:

"The choice between these three medications isn't just about weight loss numbers - it's about matching the medication to the patient's complete health profile".

Deciding between these medications involves considering factors like individual hormonal imbalances, how well side effects can be managed, insurance coverage, and long-term fertility goals.

For weight loss to truly last, these treatments need to be paired with meaningful lifestyle changes. This includes making dietary adjustments and incorporating behavioral support. Research highlights that without these changes, nearly two-thirds of lost weight is typically regained within a year.

To navigate these options effectively, it’s important to consult healthcare providers who specialize in women’s metabolic health. Oana Health provides personalized telehealth consultations with licensed professionals who understand the unique challenges of PCOS. Their tailored plans address insulin resistance, hormonal imbalances, and sustainable weight management - all from the comfort of home.

FAQs

Which is more effective for PCOS-related weight loss: Wegovy or Mounjaro?

Both Wegovy and Mounjaro are effective options for weight loss in women with PCOS, but they differ in how they work and the results they deliver. Clinical trials indicate that Mounjaro (tirzepatide) leads to slightly greater weight loss, with an average reduction of about 21% of body weight. In comparison, Wegovy (semaglutide) results in an average weight loss of around 17%. Mounjaro’s dual action as a GLP-1 and GIP receptor agonist may also help improve insulin sensitivity, which is a crucial factor for many individuals managing PCOS.

On the other hand, Wegovy stands out for its specific FDA approval for weight management and its well-documented safety profile. While it might not achieve the same degree of weight loss as Mounjaro, it remains a dependable and effective choice. Deciding between these medications should take into account personal health considerations, potential side effects, and advice from a healthcare provider.

What side effects should I expect when using Wegovy or Mounjaro for PCOS-related weight loss?

Both Wegovy and Mounjaro are known to cause side effects, with the most common being gastrointestinal issues such as nausea, vomiting, diarrhea, and stomach discomfort. These are typical reactions for medications in the GLP-1 receptor agonist category and often improve over time as your body gets used to the treatment.

In rare instances, more serious side effects can occur, including severe allergic reactions or other complications. Since Mounjaro also targets GIP receptors in addition to GLP-1 receptors, its side effect profile is similar but may vary depending on individual health factors.

If you're experiencing side effects or have concerns, it's essential to talk to your healthcare provider. They can offer personalized advice and closely monitor your progress to ensure the treatment is working safely for you.

What are the long-term safety concerns of using Wegovy or Mounjaro for managing PCOS-related weight loss?

When considering weight management options like Wegovy (semaglutide) and Mounjaro (tirzepatide) for conditions such as PCOS, it’s important to weigh potential long-term safety concerns.

Animal studies have associated Mounjaro with a risk of thyroid C-cell tumors, though it’s not yet clear if this risk extends to humans. Wegovy, on the other hand, is still under review for long-term safety, but like any medication, it may carry risks that require careful monitoring. Consulting with a healthcare provider is crucial to explore these treatments and determine the safest option tailored to your needs.